Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bausch + Lomb Corporation ( (BLCO) ) has issued an update.
Bausch + Lomb will showcase extensive new scientific data and host multiple educational events at the upcoming American Society of Cataract and Refractive Surgery meeting in Washington, D.C. The company’s presence underscores its broad portfolio, spanning minimally invasive glaucoma surgery systems, intraocular lenses, dry eye therapies, diagnostic devices and surgical platforms.
A total of 45 presentations and posters will cover real-world outcomes, clinical efficacy and safety across products such as the ELIOS MIGS system, enVista IOLs, MIEBO, XIIDRA, the Stellaris Elite system and the TENEO excimer laser. By emphasizing cataract surgery optimization, glaucoma management and dry eye treatment in both clinical trials and real-world practice, Bausch + Lomb is reinforcing its role as a key innovator in ophthalmology and strengthening its engagement with surgeons and eye-care professionals.
The most recent analyst rating on (BLCO) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
The score is most constrained by weak financial performance—multi-year net losses and negative free cash flow—despite solid revenue growth and a supportive balance sheet in the latest period. Offsetting this, the earnings call was strong with clear 2026 guidance for improved margins and EBITDA growth, and the technical setup is constructive with the stock trending above key moving averages. Valuation is held back by negative earnings and no stated dividend support.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a global eye health company that develops and markets products across vision care, ophthalmic pharmaceuticals and surgical technologies. Its portfolio targets conditions such as cataracts, glaucoma and dry eye disease, serving ophthalmologists, optometrists and surgical centers worldwide with devices, lenses and prescription treatments.
Average Trading Volume: 417,132
Technical Sentiment Signal: Buy
Current Market Cap: $5.84B
For detailed information about BLCO stock, go to TipRanks’ Stock Analysis page.